Autolus Therapeutics (AUTL) Competitors $1.95 0.00 (0.00%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.98 +0.03 (+1.49%) As of 02/21/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends AUTL vs. CGON, TARS, JANX, AGIO, NAMS, IDYA, SDGR, TVTX, BLTE, and VERAShould you be buying Autolus Therapeutics stock or one of its competitors? The main competitors of Autolus Therapeutics include CG Oncology (CGON), Tarsus Pharmaceuticals (TARS), Janux Therapeutics (JANX), Agios Pharmaceuticals (AGIO), NewAmsterdam Pharma (NAMS), IDEAYA Biosciences (IDYA), Schrödinger (SDGR), Travere Therapeutics (TVTX), Belite Bio (BLTE), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry. Autolus Therapeutics vs. CG Oncology Tarsus Pharmaceuticals Janux Therapeutics Agios Pharmaceuticals NewAmsterdam Pharma IDEAYA Biosciences Schrödinger Travere Therapeutics Belite Bio Vera Therapeutics CG Oncology (NASDAQ:CGON) and Autolus Therapeutics (NASDAQ:AUTL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, community ranking, dividends, media sentiment, valuation and earnings. Do analysts rate CGON or AUTL? CG Oncology currently has a consensus target price of $65.14, indicating a potential upside of 133.91%. Autolus Therapeutics has a consensus target price of $10.40, indicating a potential upside of 433.33%. Given Autolus Therapeutics' higher probable upside, analysts clearly believe Autolus Therapeutics is more favorable than CG Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CG Oncology 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CGON or AUTL more profitable? Autolus Therapeutics has a net margin of 0.00% compared to CG Oncology's net margin of -10,642.98%. CG Oncology's return on equity of -18.97% beat Autolus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CG Oncology-10,642.98% -18.97% -15.36% Autolus Therapeutics N/A -63.65%-36.54% Do insiders and institutionals hold more shares of CGON or AUTL? 26.6% of CG Oncology shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has better valuation & earnings, CGON or AUTL? CG Oncology has higher earnings, but lower revenue than Autolus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCG Oncology$684K3,095.99-$48.61MN/AN/AAutolus Therapeutics$1.70M305.22-$208.38M-$1.21-1.61 Does the media refer more to CGON or AUTL? In the previous week, CG Oncology had 3 more articles in the media than Autolus Therapeutics. MarketBeat recorded 5 mentions for CG Oncology and 2 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 1.52 beat CG Oncology's score of 1.03 indicating that Autolus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Autolus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Does the MarketBeat Community believe in CGON or AUTL? Autolus Therapeutics received 206 more outperform votes than CG Oncology when rated by MarketBeat users. However, 91.30% of users gave CG Oncology an outperform vote while only 67.96% of users gave Autolus Therapeutics an outperform vote. CompanyUnderperformOutperformCG OncologyOutperform Votes2191.30% Underperform Votes28.70%Autolus TherapeuticsOutperform Votes22767.96% Underperform Votes10732.04% SummaryCG Oncology beats Autolus Therapeutics on 9 of the 16 factors compared between the two stocks. Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AUTL vs. The Competition Export to ExcelMetricAutolus TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$518.88M$3.12B$5.78B$8.98BDividend YieldN/A1.57%4.78%3.85%P/E Ratio-1.6130.1126.4618.82Price / Sales305.22412.67457.0180.76Price / CashN/A183.5344.0437.47Price / Book3.053.567.634.64Net Income-$208.38M-$71.72M$3.18B$245.69M7 Day Performance-4.41%-2.45%-1.82%-2.63%1 Month Performance-10.96%0.36%0.22%-2.37%1 Year Performance-68.55%-11.50%17.49%13.65% Autolus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AUTLAutolus Therapeutics2.9264 of 5 stars$1.95flat$10.40+433.3%-68.5%$518.88M$1.70M-1.61330Positive NewsCGONCG Oncology1.8412 of 5 stars$28.52+0.1%$63.88+124.0%-38.5%$2.17B$200,000.000.0061News CoverageTARSTarsus Pharmaceuticals1.4247 of 5 stars$50.22-3.8%$56.00+11.5%+58.8%$1.92B$17.45M-13.1850Gap UpJANXJanux Therapeutics3.1282 of 5 stars$36.37-2.2%$89.90+147.2%+174.0%$1.91B$13.05M-31.0930AGIOAgios Pharmaceuticals4.3439 of 5 stars$33.22-0.2%$56.33+69.6%+31.4%$1.89B$26.82M2.92390Earnings ReportShort Interest ↓NAMSNewAmsterdam Pharma3.2893 of 5 stars$19.91+2.6%$41.60+108.9%-13.9%$1.84B$14.09M0.004Upcoming EarningsIDYAIDEAYA Biosciences3.8329 of 5 stars$21.00+1.2%$53.58+155.2%-50.9%$1.82B$23.39M-9.0180Gap UpSDGRSchrödinger1.9488 of 5 stars$24.85+1.7%$32.11+29.2%-24.6%$1.81B$216.67M-10.62790Upcoming EarningsTVTXTravere Therapeutics2.9598 of 5 stars$22.91-3.4%$27.77+21.2%+178.9%$1.79B$145.24M-5.04460Earnings ReportAnalyst ForecastNews CoverageBLTEBelite Bio3.2124 of 5 stars$56.00-1.0%$96.33+72.0%+26.3%$1.78BN/A-50.4510Positive NewsVERAVera Therapeutics2.4205 of 5 stars$27.46-19.7%$65.44+138.3%-35.8%$1.74BN/A-10.5240High Trading Volume Related Companies and Tools Related Companies CG Oncology Competitors Tarsus Pharmaceuticals Competitors Janux Therapeutics Competitors Agios Pharmaceuticals Competitors NewAmsterdam Pharma Competitors IDEAYA Biosciences Competitors Schrödinger Competitors Travere Therapeutics Competitors Belite Bio Competitors Vera Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AUTL) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AUTL Stock Alerts